African-Americans are four times more likely to experience chronic kidney disease and failure than Caucasians. Kidney transplants have more than doubled in recipients above 65 years of age from 2000-2008. And the prevalence of end-stage renal disease, or kidney failure, in the U.S. has continued to increase, particularly among elderly patients and African-Americans, according to the National Institutes of Health. Despite knowledge of the disparity, researchers and clinicians are seeking a new understanding of why the age and race gap exists. Now, a new University at Buffalo study led by Kathleen Tornatore, Pharm.D., professor in the department of pharmacy practice in the School of Pharmacy and Pharmaceutical Sciences, aims to answer these questions by exploring the effects of age, race and sex on immunosuppressive medication and immune responses of renal transplant patients.
Funded by a five-year, $3.5 million grant from the National Institutes of Aging, the study aims to bridge the gap between current, nonspecific clinical methods and personalized medicine for high-risk patients.
Kathleen Tornatore, Pharm.D.